Form 4: Apellis CMO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Medical Officer, Caroline Baumal, sold 1,882 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction involving company common stock.
• On January 20, 2026, Baumal sold 1,882 shares of Apellis common stock at a price of $19.7929 per share.
• The sale was conducted to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that vested on January 16, 2026.
• Following this transaction, Baumal beneficially owns 89,324 shares of Apellis common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale to cover tax obligations on vested equity, which is a common occurrence for executives and does not reflect a change in sentiment towards the company's prospects.

Positives

• The transaction is a routine, non-discretionary sale to cover tax liabilities arising from the vesting of Restricted Stock Units, which is a common and expected practice for executives receiving equity compensation.

Negatives

• The sale represents a minor reduction in direct insider ownership, though it is for a specific, non-discretionary tax purpose rather than a discretionary sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This type of insider transaction, specifically the sale of shares to cover tax withholding on vested equity awards, is a common and routine event across all industries for executives of publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The reported transaction is a standard Form 4 filing for a tax-related sale of shares, which is a common practice for executives across publicly traded companies when Restricted Stock Units (RSUs) vest. This aligns with typical corporate compensation and tax management practices observed in the industry.

Stakeholder Impact

• Shareholders: The sale represents a very minor dilution effect, but as a routine tax-related transaction, it is generally not indicative of a lack of confidence in the company's future by the insider.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by a Chief Medical Officer to cover tax obligations on vested Restricted Stock Units. This type of transaction is common and does not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Caroline Baumal, Chief Medical Officer, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting, Rule 10b5-1